Table 1. Baseline characteristics of patients.
TCE, triple class experienced; s.d., standard deviation; ARV, antiretroviral; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; cART, combination antiretroviral treatment
| TCE n (%) |
Not TCE n (%) |
|
|---|---|---|
| Total | 526 (100) | 972 (100) |
| Age (years) | ||
| Mean (s.d.) | 40 (10) | 39 (10) |
| <30 | 70 (13) | 133 (14) |
| 30–39 | 212 (40) | 395 (40) |
| 40–49 | 156 (30) | 279 (29) |
| 50+ | 88 (17) | 165 (17) |
| Gender | ||
| Male | 492 (93) | 909 (93) |
| Female | 33 (6) | 59 (6) |
| Transgender | 1 (<1) | 4 (<1) |
| Exposure | ||
| Homosexual | 389 (74) | 679 (70) |
| Other | 134 (25) | 281 (29) |
| Missing | 3 (<1) | 12 (1) |
| Prior AIDS | ||
| No | 441 (84) | 884 (91) |
| Yes | 85 (16) | 88 (9) |
| Hepatitis B | ||
| Negative or not tested | 494 (94) | 924 (95) |
| Positive | 32 (6) | 48 (5) |
| Hepatitis C | ||
| Negative or not tested | 460 (87) | 874 (90) |
| Positive | 66 (13) | 98 (10) |
| Prior ARV | ||
| No | 313 (60) | 744 (77) |
| Yes | 213 (40) | 228 (23) |
| First cART regimen | ||
| NRTI ± PI, no NNRTI | 321 (61) | 377 (39) |
| NNRTI + PI, ±NRTI | 52 (10) | 6 (<1) |
| NRTI + NNRTI, no PI | 153 (29) | 589 (61) |
| No. of drugs in first cART regimen | ||
| 3 | 475 (90) | 942 (97) |
| 4+ | 51 (10) | 30 (3) |
| CD4 (cells µL−1)A | ||
| Median (IQR) | 297 (150–443) | 312 (180–480) |
| <200 | 134 (25) | 211 (22) |
| 200–299 | 55 (10) | 148 (15) |
| 300–499 | 119 (23) | 226 (23) |
| 500+ | 69 (13) | 183 (19) |
| Missing | 149 (28) | 204 (21) |
| Viral load (copies mL−1)A | ||
| Median (IQR) | 70 794 (9700–290 000) | 53 000 (10 000–171 500) |
| ≤400 | 25 (5) | 89 (9) |
| 401–10 000 | 72 (14) | 100 (10) |
| 10 000+ | 276 (52) | 566 (58) |
| Missing | 153 (29) | 217 (22) |
| Year started cART | ||
| 1997 | 260 (49) | 215 (22) |
| 1998–99 | 174 (33) | 281 (29) |
| 2000–03 | 76 (14) | 268 (28) |
| 2004+ | 16 (3) | 208 (21) |
A
The closest measure within 6 months before baseline.